CLSI Validation of Exchangeable Copper Determination in Serum by ICP-MS: A Focus on Alzheimer’s Disease and Wilson Disease
Biomolecules · 2025
DOI: 10.3390/biom15060788 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Biomolecules, 2025. Verfasst von Rosanna Squitti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Science, Research and Development Division, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Copper, Hepatolenticular Degeneration, Mass Spectrometry. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Copper dyshomeostasis has been implicated in a subset of Alzheimer’s disease (AD) patients, characterized by elevated non-ceruloplasmin-bound copper (non-Cp Cu). However, traditional methods for estimating non-Cp Cu are indirect and analytically imprecise. This study introduces and validates a direct assay for exchangeable copper (ExcCu) by inductively coupled plasma-mass spectrometry (ICP-MS), compliant with Clinical and Laboratory Standards Institute (CLSI) guidelines.
Methods
We performed analytical validation of the ExcCu assay following CLSI protocols (EP5, EP6, EP7, EP9, EP15, and EP28). ExcCu and other copper-related biomarkers were quantified in serum samples from 154 healthy controls, 82 AD patients, and 10 patients with Wilson disease (WD). Diagnostic performance was evaluated via receiver operating characteristic (ROC) curve analysis, and inter-method agreement was assessed using Bland–Altman plots.
Results
The ExcCu assay demonstrated excellent linearity, precision (CV < 6%), and inter-laboratory reproducibility. Among AD patients, ExcCu levels were significantly elevated compared to controls (p < 0.001). ExcCu distinguished AD from controls with an AUC of 0.80 and a specificity of 95%. Compared to non-Cp Cu, ExcCu yielded no negative values and showed reduced bias. The relative exchangeable copper (REC) index was more effective in differentiating AD from WD (AUC = 0.88).
Conclusions
The validated ExcCu assay overcomes the limitations of the traditional non-Cp Cu calculation, offering a reliable biomarker for copper-related AD subtypes. Its high specificity supports its use in patient stratification, potentially contributing to personalized approaches in AD diagnosis and therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Science, Research and Development Division, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy.
- Department of Theoretical and Applied Sciences, eCampus University, Viale Massenzio Masia, 26, 22100 Como, Italy.
- Department of Biochemistry, All India Institute of Medical Sciences, Kalyani 741245, West Bengal, India.
- Department of Clinical Laboratory, St. Ivan Rilski University Hospital, Medical University, 1431 Sofia, Bulgaria.
- Department of Neuroscience and the Experimental Alzheimer Center, Fatebenefratelli Roman Province, Via Cassia 600, 00189 Rome, Italy.
ORCID-Profile: Rosanna Squitti, Amit Pal, Irena D Ivanova
Zitieren
APA
Squitti, R., Pal, A., Ivanova, I. D., Marianetti, M., & Rongioletti, M. (2025). CLSI Validation of Exchangeable Copper Determination in Serum by ICP-MS: A Focus on Alzheimer’s Disease and Wilson Disease. Biomolecules. https://doi.org/10.3390/biom15060788
Vancouver
Squitti R, Pal A, Ivanova ID, Marianetti M, Rongioletti M. CLSI Validation of Exchangeable Copper Determination in Serum by ICP-MS: A Focus on Alzheimer’s Disease and Wilson Disease. Biomolecules. 2025. doi:10.3390/biom15060788
BibTeX
@article{Squitti2025,
author = {Squitti, Rosanna and Pal, Amit and Ivanova, Irena D and Marianetti, Massimo and Rongioletti, Mauro},
title = {CLSI Validation of Exchangeable Copper Determination in Serum by ICP-MS: A Focus on Alzheimer’s Disease and Wilson Disease},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15060788}
}
EUVIMED